Triple Anti-Parasitic Therapy (Ivermectin, Mebendazole, Fenbendazole) in Repurposed Oncology: A Retrospective Analysis of 25 Case Reports (2026)
Abstract Objective: To systematically evaluate the clinical outcomes, treatment protocols, confounding variables, and safety profiles of 25 retrospective case reports featuring advanced, refractory malignancy patients who integrated the triple repurposed anthelmintic regimen (Ivermectin, Mebendazole, and Fenbendazole). Methods: A multi-parametric review of 25 patient case histories was performed. Data extraction targeted tumor heterogeneity, the presence of concomitant standard-of-care (SoC) therapies, dosing schedules (metronomic vs. pulsed), objective biomarker/radiographic endpoints, and hepatic tolerability profiles. Results: The case series revealed distinct clusters of efficacy, particularly in highly metabolic solid malignancies and intracranial lesions. A significant cross-sensitization signal was noted in patients concurrently undergoing immune checkpoint inhibition. While dosing protocols varied between continuous metronomic exp...